These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 32883007)

  • 1. Natural Killer Cell Dysfunction and Its Role in COVID-19.
    van Eeden C; Khan L; Osman MS; Cohen Tervaert JW
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
    Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
    Front Immunol; 2020; 11():1512. PubMed ID: 32655581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection.
    Huizinga GP; Singer BH; Singer K
    Endocrinology; 2020 Nov; 161(11):. PubMed ID: 32880654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
    Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
    Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perforin and resistance to SARS coronavirus 2.
    Cunningham L; Simmonds P; Kimber I; Basketter DA; McFadden JP
    J Allergy Clin Immunol; 2020 Jul; 146(1):52-53. PubMed ID: 32422144
    [No Abstract]   [Full Text] [Related]  

  • 6. Surviving COVID-19: A disease tolerance perspective.
    Ayres JS
    Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020.
    Manickam C; Sugawara S; Reeves RK
    PLoS Pathog; 2020 Aug; 16(8):e1008820. PubMed ID: 32845937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cells: A double edge sword against SARS-CoV-2.
    Masselli E; Vaccarezza M; Carubbi C; Pozzi G; Presta V; Mirandola P; Vitale M
    Adv Biol Regul; 2020 Aug; 77():100737. PubMed ID: 32773100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
    Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term infection of SARS-CoV-2 changed the body's immune status.
    Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
    Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
    Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
    Jewett A
    Front Immunol; 2020; 11():1692. PubMed ID: 32754162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.
    Cunha LL; Perazzio SF; Azzi J; Cravedi P; Riella LV
    Front Immunol; 2020; 11():1748. PubMed ID: 32849623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?
    Mondal R; Lahiri D; Deb S; Bandyopadhyay D; Shome G; Sarkar S; Paria SR; Thakurta TG; Singla P; Biswas SC
    J Thromb Thrombolysis; 2020 Oct; 50(3):567-579. PubMed ID: 32627126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response.
    Hannan MA; Rahman MA; Rahman MS; Sohag AAM; Dash R; Hossain KS; Farjana M; Uddin MJ
    Immunol Lett; 2020 Oct; 226():38-45. PubMed ID: 32659267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.